Clinical Trial Update: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating obinutuzumab, rituximab, polatuzumab vedotin, and venetoclax in relapsed/refractory follicular lymphoma or diffuse large …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• Venetoclax (venetoclax)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-10